Xtl Biopharmaceuticals (XTLB) Receivables - Net (2009 - 2025)

Xtl Biopharmaceuticals (XTLB) has reported Receivables - Net for 11 consecutive years, with $99000.0 the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Net changed 0.0% year-over-year to $99000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $99000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $99000.0, changed 0.0% from the prior year.
• Receivables - Net steadied at $99000.0 in Q4 2025 per XTLB's latest filing, from $99000.0 in the prior quarter.
• Over the last five years, Receivables - Net for XTLB reached as high as $8.0 million in Q4 2021 and fell as low as $99000.0 in Q4 2024.
• A 5-year average of $4.8 million and a median of $8.0 million in 2021 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net changed 0.0% — and 2024, when it plunged 98.76%.
• Year by year, Receivables - Net stood at $8.0 million in 2021, then changed by 0.0% to $8.0 million in 2022, then changed by 0.0% to $8.0 million in 2023, then tumbled by 98.76% to $99000.0 in 2024, then changed by 0.0% to $99000.0 in 2025.
• According to Business Quant data, Receivables - Net over the past three periods registered $99000.0, $99000.0, and $8.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.